

## Total Synthesis of (+)-*erythro*-*N*-Lauroyldocosasphinga-4,8-dienine from *Anemonia sulcata* and Determination of the Absolute Configuration

Masako Nakagawa,\* Akihiko Tsuruoka, Jun Yoshida, and Tohru Hino\*


Faculty of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Chiba, 260, Japan

A new sphingosine derivative (1) from *Anemonia sulcata* has been synthesized and the *L-erythro* configuration determined.


Several reports of the occurrence of the dienic long-chain base, sphingadienine, have appeared in recent years.<sup>1</sup> A new sphingosine derivative, *erythro*-docosasphinga-4,8-dienine, has recently been isolated and characterized as an *N*-lauroyl derivative from *Anemonia sulcata* collected near Sousse; its

structure was reported to be (1).<sup>2</sup> However, the absolute configuration of (1) has not been determined yet, although the relative stereochemistry at C-2 and C-3 has been determined to be *erythro* by the coupling constants between H-2 and H-3.


We have reported a simple method for preparation of



**Scheme 1.** Reagents and conditions: i, HO[CH<sub>2</sub>]<sub>2</sub>NO<sub>2</sub> (3.5 equiv.), Et<sub>3</sub>N, 4 °C, 4 days; ii, Me<sub>2</sub>C(OMe)<sub>2</sub>-acetone, PPTS (0.1 equiv.), reflux, 16 h; iii, Et<sub>3</sub>N, reflux, 5 h; iv, Al-Hg, tetrahydrofuran (THF)-H<sub>2</sub>O, room temp., 1 h; v, Me[CH<sub>2</sub>]<sub>10</sub>COCl (1 equiv.), Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 12 h; vi, pyridinium toluene-*p*-sulphonate (PPTS) (1.0 equiv.), MeOH, room temp., 2 days; vii, Ph<sub>3</sub>CCl (2 equiv.), dimethylaminopyridine (DMAP) (3 equiv.), pyridine, 100 °C, 1.5 h; viii, (*S*)-*O*-methylmandelyl chloride, pyridine, benzene, room temp., 40 min, separation; ix, *p*-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H (1.3 equiv.), MeOH, room temp.; x, MeONa (4 equiv.), MeOH, room temp.



**Scheme 2.** Reagents and conditions: i,  $\text{Bu}^n_2\text{BOSO}_2\text{CF}_3$  (1.1 equiv.),  $\text{Et}_3\text{N}$  (1.4 equiv.),  $\text{Et}_2\text{O}$ ,  $-78^\circ\text{C}$ , then room temp., 1.5 h; ii, (2),  $-78^\circ\text{C}$ , 30 min, then  $0^\circ\text{C}$ , 2 h; iii,  $\text{NaN}_3$  (2 equiv.), dimethylformamide (DMF), room temp., 2.5 h; iv,  $\text{MeOMgBr}$  (1.1 equiv.),  $\text{MeOH}$ ,  $0^\circ\text{C}$ , 5 min; v,  $\text{LiAlH}_4$  (3 equiv.),  $\text{Et}_2\text{O}$ ,  $0^\circ\text{C}$ , 15 min, then room temp., 1 h; vi, camphorsulphonic acid (CSA; 1 equiv.),  $\text{Me}_2\text{C}(\text{OMe})_2$ , reflux, 1 h.



**Scheme 3.** Reagents and conditions: i, THF,  $-23^\circ\text{C}$ , 1.5 h; ii, *p*- $\text{MeC}_6\text{H}_4\text{SO}_3\text{H}$  (0.1 equiv.),  $\text{MeOH}$ , room temp., 6.5 h; iii, conc.  $\text{HCl}$ ,  $\text{AcOEt}$ , room temp., 50 min; iv,  $\text{LiAlH}_4$  (excess),  $\text{MeO}[\text{CH}_2]_2\text{OMe}$ , reflux, 10 h; v,  $\text{Me}_2\text{C}(\text{OMe})_2$ , CSA (1 equiv.), reflux, 1 h.

*erythro*-sphingosine<sup>3</sup> which was applied to the total synthesis of cerebroside  $\text{B}_{1b}$ .<sup>4</sup> We now report the total synthesis of (1) by three different approaches and the determination of its absolute configuration.

The first approach to (1) involved the optical resolution of the racemic *erythro*-ceramide ( $\pm$ )-(1), obtained by our method which included the 1,2-addition reaction of nitroethanol to the dienal (2)<sup>3,4</sup> (Scheme 1). Treatment of the dienal (2) with nitroethanol gave the nitrodiol ( $\pm$ )-(3) (71%) as a mixture of *erythro*- and *threo*-isomers which was converted to the *erythro*-acetone ( $\pm$ )-(4) [66% from (3)]. Reduction of ( $\pm$ )-(4), followed by acylation with lauroyl chloride, gave ( $\pm$ )-(5). Deprotection of ( $\pm$ )-(5) provided the *erythro*-*N*-lauroyldocosasphinga-4,8-dienine ( $\pm$ )-(1), m.p.  $75.5^\circ\text{C}$  [54% from (4)].

Tritylation of ( $\pm$ )-(1), followed by esterification with (*S*)-*O*-methylmandelyl chloride<sup>5</sup> afforded a mixture of diastereoisomers (7) and (8),<sup>†</sup> separable by column chromatography.

Detritylation and hydrolysis of the mandelates (7) and (8) afforded the corresponding enantiomeric alcohols (+)-(1) {m.p.  $79.0$ – $80.5^\circ\text{C}$ ;  $[\alpha]_D +2.25^\circ$  (*c* 0.844,  $\text{CHCl}_3$ ); 18% from ( $\pm$ )-(1)} and (–)-(1) {m.p.  $79.0$ – $82.0^\circ\text{C}$ ;  $[\alpha]_D -2.47^\circ$  (*c* 1.094,  $\text{CHCl}_3$ ); 14% from ( $\pm$ )-(1)},<sup>‡</sup> respectively. The spectral data (IR, NMR, mass) of the synthetic (+)-(1) and (–)-(1) were identical with those of the natural product (lit. m.p. reported<sup>2</sup> as  $297$ – $298^\circ\text{C}$ ; the m.p. of the natural products kindly given by Dr. Guyot was  $\sim 74^\circ\text{C}$  in our hands).

With the optically active (1) thus available by resolution, we then attempted two different chiral syntheses of (–)-(1) by unequivocal methods in order to determine the absolute configuration of the natural product (+)-(1).

The first approach involved the stereoselective aldol addi-

<sup>†</sup> The absolute configuration of the *O*-methylmandelate esters (7) [ $\delta_{\text{H}}$  3.45 (2-H) and 5.42 (4-H)] and (8) [ $\delta_{\text{H}}$  3.41 (2-H) and 5.43 (4-H)] was estimated to be (2*R*,3*S*) and (2*S*,3*R*), respectively.<sup>5</sup>

<sup>‡</sup> (–)-(1):  $\nu_{\text{max}}$  (KBr) 3280, 1635, and  $960\text{ cm}^{-1}$ ;  $\delta_{\text{H}}$  5.78 (1H, m, 5-H), 5.55 (1H, dd, *J* 15.4 and 6.3 Hz, 4-H), 5.45–5.34 (2H, m, 8- and 9-H), 4.32 (1H, m, 3-H), 3.95 (1H, dt, *J* 11.3 and 3.9 Hz, 1-H), 3.91 (1H, m, 2-H), 3.70 (1H, ddd, *J* 11, 7.7, and 3.3 Hz, 1-H), 2.73 (1H, d, *J* 5.0 Hz,  $\text{CHOH}$ , exch.), and 2.68 (1H, dd, *J* 7.4 and 3.9 Hz,  $\text{CH}_2\text{OH}$ , exch.); *m/z* 535 (0.76,  $M^+$ ), 517 (2.09,  $M^+ - \text{H}_2\text{O}$ ), 225 (52.19), and 60 (100%); satisfactory elemental analyses were obtained.

tion of (2) with Evans' chiral haloacetate enolate,<sup>6</sup> prepared from the bromoacetyloxazolidin-2-one (9), di-*n*-butylboryl trifluoromethanesulphonate (1.1 equiv.), and Et<sub>3</sub>N, which afforded the bromo aldol adduct (10) {89%, [ $\alpha$ ]<sub>D</sub> +43° (*c* 1.025, CHCl<sub>3</sub>)} with >92% diastereoisomeric purity. Treatment of (10) with sodium azide in dimethylformamide (DMF) gave the corresponding azide (11) (99%). Methanolysis of (11) with methoxymagnesium bromide afforded the enantiomerically pure  $\alpha$ -azido ester (12) (70%). LiAlH<sub>4</sub> reduction of (12) gave sphingadienine (13) which was immediately converted to the acetone (14) [31% from (12)]. Acylation of (14) with lauroyl chloride yielded the *N*-lauroyl derivative (5) (95%), which was deprotected to give (2*S*,3*R*)-(-)-(1) {93%, m.p. 80–81.5 °C, [ $\alpha$ ]<sub>D</sub> -3.20° (*c* 1.769, CHCl<sub>3</sub>)} (Scheme 2).

In order rigorously to confirm the stereochemistry of (-)-(1), another approach to (-)-(1) by a stereoselective synthesis from *L*-serine<sup>7</sup> was carried out (Scheme 3). Reaction of the protected *L*-serinal (16) with nonadec-5-en-1-ynyllithium (15) provided the *erythro*-alkynol (17) {47%, [ $\alpha$ ]<sub>D</sub> -38.1° (*c* 1.000, CHCl<sub>3</sub>)} together with the *threo*-isomer (2%). Treatment of (17) with *p*-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H in MeOH resulted in selective cleavage of the acetal moiety, leading to the 1,3-diol (18). Acid hydrolysis of (18) to give (19) followed by selective LiAlH<sub>4</sub> reduction<sup>8</sup> gave (13) which was converted to (14) without purification. Acylation of (14) followed by deprotection gave the crystalline (2*S*,3*R*)-(-)-(1) {m.p. 78–80 °C, [ $\alpha$ ]<sub>D</sub> -3.47° (*c* 0.336, CHCl<sub>3</sub>); lit.<sup>2</sup> m.p. 297–298 °C, [ $\alpha$ ]<sub>D</sub> +2.94° (CHCl<sub>3</sub>)}.

Compound (1) was unambiguously shown by <sup>1</sup>H NMR analysis of (14) to have the *erythro*-relative configuration.

Since the natural product (1) has been reported to have a positive optical rotation {[ $\alpha$ ]<sub>D</sub> +2.94° (CHCl<sub>3</sub>)}; the present synthesis allows the absolute configuration of the natural product to be assigned as *L-erythro* [(2*R*,3*S*)-(+)-*erythro-N*-lauroyldocosasphinga-4,8-dienine].

We thank Dr. Guyot, Musée National d'Histoire Naturelle, for a generous gift of the natural product. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan. We are also grateful to the Japan Foundation for Optically Active Compounds.

Received, 28th November 1989; Com. 9/05085J

## References

- 1 K.-A. Karlsson, in 'Biological Membranes,' ed. D. Chapman, Academic Press, London, 1982, vol. 4, p. 1.
- 2 K. Chebaane and M. Guyot, *Tetrahedron Lett.*, 1986, **27**, 1495.
- 3 T. Hino, K. Nakayama, M. Taniguchi, and M. Nakagawa, *J. Chem. Soc., Perkin Trans. 1*, 1986, 1687.
- 4 M. Nakagawa, S. Kodato, K. Nakayama, and T. Hino, *Tetrahedron Lett.*, 1987, **28**, 6281.
- 5 B. M. Trost, J. L. Belletire, S. Godleski, P. G. McDougal, J. M. Balkovec, J. J. Baldwin, M. E. Christy, G. S. Ponticello, S. L. Varga, and J. P. Springer, *J. Org. Chem.*, 1986, **51**, 2370.
- 6 D. A. Evans, E. B. Sjogren, A. E. Weber, and R. E. Conn, *Tetrahedron Lett.*, 1987, **28**, 39.
- 7 S. Nimkar, D. Menaldino, A. H. Merrill, and D. Liotta, *Tetrahedron Lett.*, 1988, **29**, 3037; H.-E. Radunz, R. M. Devant, and V. Eiermann, *Liebigs Ann. Chem.*, 1988, 1103.
- 8 W. T. Borden, *J. Am. Chem. Soc.*, 1970, **92**, 4898.